Status: Recruiting
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \<18 years of age with somatostatin receptor (SSTR)-positive tumors.
Participants needed: 20
Trial details
Phase: Phase 1Age: 24-18Biological sex: AllType: InterventionalSponsor: ITM Solucin GmbHUpdated: May 1, 2026Locations: 5
Eligibility criteria
Participants aged ≥ 2 years and < 18 years [+6]
Known hypersensitivity to Lutetium Lu 177 Edotreotide, DOTA/Edotreotide, or exci... [+12]